Ignite Creation Date:
2025-12-24 @ 5:55 PM
Ignite Modification Date:
2025-12-29 @ 5:44 PM
Study NCT ID:
NCT01522768
Status:
COMPLETED
Last Update Posted:
2023-11-01
First Post:
2012-01-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-03
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-20
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-25
First Submit QC Date:
None
Study First Post Date:
2012-02-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-10-11
Results First Submit QC Date:
None
Results First Post Date:
2023-11-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-11
Last Update Post Date:
2023-11-01
Last Update Post Date Type:
ACTUAL